Related Experiment Video
Updated: Aug 6, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
Inhibition of cyclin-dependent kinase 5 activity protects pancreatic beta cells from glucotoxicity
Mariano Ubeda1, J Michael Rukstalis, Joel F Habener
1Laboratory of Molecular Endocrinology, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Type 2 diabetes (T2D) and Alzheimer disease are degenerative diseases that may share common pathophysiologic mechanisms. Neuronal dysfunction in Alzheimer patients has been linked to overactivity of the cyclin-dependent kinase 5 (CDK5) and its activator p35. Both of these proteins are expressed in the insulin-producing beta cells of the pancreas. Further, glucose enhances p35 gene expression, promoting the formation of active p35/CDK5 complexes that regulate the expression of the insulin gene. In T2D, chronic elevations of glucose, glucotoxicity, impair beta cell function. We therefore postulated that CDK5 and p35 may be responsible for this beta cell impairment and that inhibition of CDK5 might have a beneficial effect. To test this hypothesis, the pancreatic cell line INS-1 was selected as a known in vitro model of glucotoxicity, and roscovitine (10 mum) was used as a CDK5 inhibitor. Chronic exposure of INS-1 cells to high glucose (20-30 mm) reduced both insulin mRNA levels and the activity of an insulin promoter reporter gene. Inhibition of CDK5 prevented this decrease of insulin gene expression. We used DNA binding (gel shift) assays and Western immunoblots to demonstrate that cellular levels of the transcription factor PDX-1, normally decreased by glucotoxicity, were preserved with CDK5 inhibition, as was the binding of PDX-1 to the insulin promoter. Analyses of nuclear and cytoplasmic PDX-1 protein levels revealed that CDK5 inhibition restores nuclear PDX-1, without affecting its cytoplasmic concentration, suggesting that CDK5 regulates the nuclear/cytoplasm partitioning of PDX-1. Using a Myc-tagged PDX-1 construct, we showed that the translocation of PDX-1 from the nucleus to the cytoplasm during glucotoxic conditions was prevented when CDK5 was inhibited. These studies indicate that CDK5 plays a role in the loss of beta cell function under glucotoxic conditions and that CDK5 inhibitors could have therapeutic value for T2D.
Insights
Cyclin-dependent kinase 5 (CDK5) inhibition preserves pancreatic beta cell function in type 2 diabetes by maintaining PDX-1 nuclear localization, suggesting CDK5 inhibitors may treat this condition.
Area of Science:
- Endocrinology
- Molecular Biology
- Neuroscience
Background:
- Type 2 diabetes (T2D) and Alzheimer's disease share potential common mechanisms.
- Overactive cyclin-dependent kinase 5 (CDK5) and p35 are implicated in neuronal dysfunction and may affect pancreatic beta cells.
Purpose of the Study:
- To investigate the role of CDK5 and p35 in glucotoxicity-induced beta cell impairment in T2D.
- To determine if CDK5 inhibition could protect beta cell function.
Main Methods:
- Utilized the INS-1 pancreatic cell line as an in vitro model of glucotoxicity.
- Employed roscovitine as a CDK5 inhibitor.
- Assessed insulin gene expression, insulin promoter activity, and PDX-1 transcription factor levels via reporter assays, gel shifts, and Western immunoblots.
Main Results:
- High glucose reduced insulin mRNA and promoter activity, which was prevented by CDK5 inhibition.
- CDK5 inhibition preserved PDX-1 levels and its binding to the insulin promoter under glucotoxic conditions.
- CDK5 inhibition maintained PDX-1 in the nucleus, preventing its translocation to the cytoplasm.
Conclusions:
- CDK5 plays a critical role in the loss of pancreatic beta cell function caused by glucotoxicity in T2D.
- CDK5 inhibitors demonstrate therapeutic potential for treating type 2 diabetes.
Related Concept Videos
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Inhibition of Cdk Activity
Dipeptidyl Peptidase 4 Inhibitors
Insulin Secretory Vesicles
cAMP-dependent Protein Kinase Pathways

